There are currently 3 active clinical trials seeking participants for Dyslipidemia research studies. The states with the highest number of trials for Autism participants are Florida, California, Texas and North Carolina.
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
Recruiting
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded ac... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/11/2024
Locations: Research Site, Huntsville, Alabama +62 locations
Conditions: Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of two parts (Parts A and B). 56 subjects have been planned for Part A and 141 subjects for Part B. Additional subjects may be included for the optional cohorts depending upon emerging data.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/25/2024
Locations: Research Site, Glendale, California +2 locations
Conditions: Dyslipidemia
Dyslipidemia and Diabetic Retinopathy
Recruiting
The purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(EPC) are defective in people with diabetes.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Diabetic Retinopathy, Dyslipidemia